Cost-effectiveness of pembrolizumab plus chemotherapy as first line treatment in PD-L1-positive metastatic TNBC. Supplementary Tables.
收藏DataCite Commons2024-05-16 更新2025-04-15 收录
下载链接：
https://tandf.figshare.com/articles/dataset/Cost-effectiveness_of_pembrolizumab_plus_chemotherapy_as_first_line_treatment_in_PD-L1-positive_metastatic_TNBC_Supplementary_Tables_/20253123/1
下载链接
链接失效反馈官方服务：
资源简介：
<strong>Supplementary Table S1. </strong>AIC/BIC of parametric function fitting for OS, PFS and ToT
<br>
<strong>Supplementary Table S2.</strong> AE related hospitalization costs (2021 USD)
<br>
<strong>Supplementary Table S3.</strong> Summary of scenario analyses results
<br>
<strong>Supplementary Table S4.</strong> Summary of subgroup analysis results
<br>
<strong>Supplementary Table S5.</strong> Cost-effectiveness results for pembrolizumab plus chemotherapy (weighted average) vs. chemotherapy (weighted average)
提供机构：
Taylor & Francis
创建时间：
2022-07-07
